Clinical Trial Update: A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study [Phase 4]

View source ↗

Summary

A Phase 4 NIAGARA trial comparing a new oral salivary substitute with two moisturizing mouth sprays in xerostomia due to head and neck cancer and Sjögren’s synd…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Hyposalivation
• Sjögren Syndrome
• Xerostomia

Drugs mentioned

• Moisturizing mouth spray (reference products)
• Oral salivary equivalent (NIAGARA trial product)

Snippet

Sponsor: Unither Pharmaceuticals, France | Conditions: Xerostomia, Hyposalivation | Phase 4 | Status: COMPLETED